A Rational Approach to Drug Development: The Confirmatory Phase

REFERENCES

• Kleinberg MI, Wanke LA. New approaches and technologies in drug design and discovery. Am J Health Syst Pharm 1995; 52(1323–1336)1341–1343
   Google Scholar
• Ette EI, Garg V, Jayaraj A. A rational approach to drug development: the exploratory phase. Clin Res Regul Affairs 2004, In Press
   Google Scholar
• Williams PJ, Godfrey CJ, Roy A, Chu H-M, Ette EI. Pharmacokinetic/pharmacodynamic knowledge discovery during drug development. Pharmacokinetics in Drug Development (I & II), P Bonate, D Howard. AAPS Press, Arlington 2004, In Press
   Google Scholar
• Ette EI, Williams P, Sun H, Fadiran EO, Ajayi F, Oyniah LC. The process of knowledge discovery from large pharmacokinetic data sets. J Clin Pharmacol 2001; 41: 25–34.5, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Williams PJ, Ette EI. The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's ‘Guidance for Industry: Population Pharmacokinetics’. Clin Pharmacokinet 2000; 386–395
   Google Scholar
• Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16(1)187–196, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Csajaka C, Buclin T, Fattinger K, Brunner HR, Biolaz J. Population pharmacokinetic-pharmacodynamic modeling of angiotensin receptor blockade in healthy volunteers. Clin Pharmacokinet 2002; 13: 7–152
   Google Scholar
• Olsen SC, Bockbrader H, Boyd RA, et al. Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process. Clin Pharmacokinet 2000; 38: 294–312
   Google Scholar
• Ette EI, Miller R, Gillespie WR, et al. The population approach: FDA experience. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose, LP Balant, L Aarons. Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research, Brussels 1997; 271–275
   Google Scholar
• Guidance for Industry: Population pharmacokinetics. United States Food and Drug Administration, Washington, DC 1999
   Google Scholar
• Sun H, Jones CD, Lesko L, Huang SM, Higgins K, Hu C, Machado S, Maldonado S, Williams R, Hossain M, Ette EI. Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet 1999; 37: 41–58, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Fayyad U, Piatetsky-Shapiro G, Smyth P. From data mining to knowledge discovery: an overview. Advances in Knowledge Discovery and Data Mining, U Fayyad, G Piatetsky-Shapiro, P Smyth, R Uthursamy. Calit AIII Press/MIT Press, Menlo Park 1996; 1–34
   Google Scholar
• Ette EI, Sun H, Ludden TM. Design of population pharmacokinetic studies. Proc Am Stat Assoc (Biopharmaceutics Section) 1994; 487–492
   Google Scholar
• Jones CD, Sun H, Ette EI. Designing cross-sectional pharmacokinetic studies: implications for pediatric and animal studies. Clin Res Regul Affairs 1996; 13(3–4)133–165
   Google Scholar
• Fadiran EO, Jones CD, Ette EI. Designing population pharmacokinetic studies: performance of mixed designs. Eur J Drug Metab Pharmacokinet 2000; 25: 231–239, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Lesko LJ, Woodcock J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J 2002; 2: 20–24, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Pharmacogenomics in drug development and regulatory decision-making: the genomic data submission (GDS) proposal: VGDS draft guidance. Food and Drug Administration, Rockville 2003
   Google Scholar
• Hale MD, Gillespie W, Gupta S, Tuk B, Holford N. Clinical trial simulation: streamlining your drug development process. Appl Clin Trials 1996; 5: 35–40
   Google Scholar
• Hunt CA, Guzy S, Weiner DL. A forecasting approach to accelerate drug development. Stat Med 1998; 17: 1725–1740, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bonate PL. Clinical trial simulation in drug development. Pharm Res 2000; 17: 252–256, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hale MD. Using population pharmacokinetics for planning a randomized concentration-controlled trial with a binary response. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose, LP Balant, L. Aarons. Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research, Brussels 1997; 227–35
   Google Scholar
• Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000; 68(6)677–687, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• http://www.dml.georgetown.edu/cdds/SDDGP.html, Holford NHG. Hale M, Ko HC, Steimer J-L, Sheiner LB, et al. 1999. Simulation in Drug Development: Good Practices.
   Google Scholar
• Bernstein DF, Hamrell MR. Integrating drug supply issues with strategic preclinical and clinical development. Drug Info J 2000; 90: 9–917
   Google Scholar
• Rombout F. Good pharmacokinetic practice (GPP) and logistics: a continuing challenge. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose, L Aarons, LP Balant, UA gundert-Remy, MO Karlsson, F Mentre, PL Morselli, F Rombout, M Rowland, JL Steimer, S Vozeh, 1997; 183–193, Office for Official Publications of the European Communities Luxembourg
   Google Scholar
• Grasela TH, Antal EJ, Fieder-Kelley J, et al. An automated drug concentration screening and quality assurance program for clinical trials. Drug Info J 1999; 33: 273–279
   Web of Science ®Google Scholar